TrialEuropean journal of cancer (Oxford, England : 1990)2022

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.

Evan Rosenbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.